Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Novo Nordisk · Phase 2 · Completed · Enrollment 957

NCT02453711

EudraCT 2014-001540-38

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Sema 0.05 mgn/rn/rn/rn/rn/r
Sema 0.1 mgn/rn/rn/rn/rn/r
Sema 0.2 mgn/rn/rn/rn/rn/r
Sema 0.3 mgn/rn/rn/rn/rn/r
Sema 0.4 mgn/rn/rn/rn/rn/r
Sema 0.3 mg (fast dose escalation)n/rn/rn/rn/rn/r
Sema 0.4 mg (fast dose escalation)n/rn/rn/rn/rn/r
Lira 3.0 mgn/rn/rn/rn/rn/r
Placebo Sema 0.05 mg32 participants8 participants20 participantsn/r0
Placebo Sema 0.1 mg42 participants18 participants25 participantsn/r0
Placebo Sema 0.2 mg45 participants24 participants35 participantsn/r0
Placebo Sema 0.3 mgn/rn/rn/rn/rn/r
Placebo Sema 0.4 mgn/rn/rn/rn/rn/r
Placebo Sema 0.3 mg (fast dose escalation)43 participants11 participants27 participantsn/r0
Placebo Sema 0.4 mg (fast dose escalation)49 participants17 participants38 participantsn/r0
Placebo Lira 3.0 mg46 participants11 participants29 participantsn/r0

A count stays a count. This page does not turn a count into a percent.